Drug Development

Articles

The investment will be used to advance Nemaura’s R&D programs, which include liquid vaccines that have been reformulated for administration through the skin using its micropatch drug delivery technology.

Nemaura Pharma Receives Funding to Develop Biologic Micropatch System

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

According to results from the FOURIER trial, Repatha significantly reduced the risk of cardiovascular events and death in patients with atherosclerotic cardiovascular disease.

Amgen's PCSK9 mAb Shown to Protect Against Heart Attack and Stroke

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Pump systems must be designed to meet the needs of specific processes, including preventing cross-contamination and damage due to shear forces.

Pumping Fluids in Biopharmaceutical Processing

Beata Vladovicova, PhD, is R&D manager at Saneca Pharma, www.saneca.com.

More agile techniques are improving the development of multiparticulate drug-delivery systems.

Advancements in Extrusion-Spheronization

Alexandre Juillerat, PhD, innovation senior scientist at Cellectis, discusses novel construct UCART123, an investigational agent that is on deck to be the first gene-edited T-cell product in the United States.

Honing in on the Tumor Microenvironment

The agency recommended approval of a total of eight drugs at its January 2017 meeting, two of which are biosimilars.

EMA Recommends Approval of Two Biosimilars

ADMA will acquire BPC’s plasma-based fractionation and purification plant in Boca Raton, FL and plans to resolve issues at the facility noted in an FDA warning letter.

ADMA Biologics to Acquire Plasma-Based Biologics Facility from Biotest

Researchers from Cellectis investigate how external signals in the tumor microenvironment could control the cell-surface expression and specificity of engineered CARs.

Cellectis Describes Novel CAR-T Design in New Paper

Merck will pay a one-time fee of $625 million and additional royalties to BMS and Ono Pharmaceutical to settle the patent infringement case related to Keytruda.

Merck Settles Litigation with Bristol-Myers Squibb on Use of Antibody Targeting PD-1

Researchers were not able to replicate all of the findings in five highly-cited cancer biology papers.

Formulation and Drug Delivery